Chugai Pharmaceutical Co Ltd
TSE:4519

Watchlist Manager
Chugai Pharmaceutical Co Ltd Logo
Chugai Pharmaceutical Co Ltd
TSE:4519
Watchlist
Price: 6 920 JPY 0.55% Market Closed
Market Cap: 11.6T JPY
Have any thoughts about
Chugai Pharmaceutical Co Ltd?
Write Note

Chugai Pharmaceutical Co Ltd
Effect of Foreign Exchange Rates

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Chugai Pharmaceutical Co Ltd
Effect of Foreign Exchange Rates Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Effect of Foreign Exchange Rates CAGR 3Y CAGR 5Y CAGR 10Y
Chugai Pharmaceutical Co Ltd
TSE:4519
Effect of Foreign Exchange Rates
ÂĄ3.2B
CAGR 3-Years
6%
CAGR 5-Years
N/A
CAGR 10-Years
16%
Takeda Pharmaceutical Co Ltd
TSE:4502
Effect of Foreign Exchange Rates
-ÂĄ17.1B
CAGR 3-Years
N/A
CAGR 5-Years
20%
CAGR 10-Years
N/A
Daiichi Sankyo Co Ltd
TSE:4568
Effect of Foreign Exchange Rates
-ÂĄ33.3B
CAGR 3-Years
N/A
CAGR 5-Years
-32%
CAGR 10-Years
N/A
Otsuka Holdings Co Ltd
TSE:4578
Effect of Foreign Exchange Rates
-ÂĄ20.7B
CAGR 3-Years
N/A
CAGR 5-Years
-21%
CAGR 10-Years
N/A
S
Shionogi & Co Ltd
TSE:4507
Effect of Foreign Exchange Rates
ÂĄ7.3B
CAGR 3-Years
-3%
CAGR 5-Years
N/A
CAGR 10-Years
17%
Astellas Pharma Inc
TSE:4503
Effect of Foreign Exchange Rates
-ÂĄ1.2B
CAGR 3-Years
N/A
CAGR 5-Years
42%
CAGR 10-Years
N/A
No Stocks Found

Chugai Pharmaceutical Co Ltd
Glance View

Market Cap
11.4T JPY
Industry
Pharmaceuticals
Economic Moat
Narrow

Chugai Pharmaceutical Co., Ltd., a pivotal player in the pharmaceutical industry, finds its roots deeply intertwined with innovations in biotechnology. Established in Tokyo, Chugai has carved out a niche by focusing on the development and distribution of prescription pharmaceuticals tailored to address some of the most challenging medical conditions. The company's collaboration with Roche, a global healthcare leader, has strategically positioned it within the Roche Group, allowing access to an expansive trove of research and development resources. This partnership amplifies Chugai's innovative efforts, particularly in biologics and oncology, where they develop antibodies and therapies that have been instrumental in advancing clinical treatments worldwide. The synergy of Chugai's science-driven approach, coupled with Roche's global reach, has fostered a dynamic research environment that continues to push the boundaries of medical treatment possibilities. Revenue streams for Chugai are primarily anchored in the research, development, and subsequent commercialization of novel pharmaceuticals. The company gains its financial strength through successful product launches, sustained sales of flagship products, and collaborative research agreements. Chugai's extensive pipeline, particularly in the fields of oncology, immunology, and renal diseases, reflects a strategic emphasis on addressing unmet medical needs, with a considerable portion of their earnings reinvested into further research. Additionally, strategically negotiated licensing agreements allow Chugai to bolster its financial health by sharing its innovations with other industry players, maximizing distribution channels while ensuring a steady cash influx. Through this intricate balance of innovation, strategic partnerships, and a robust commercial network, Chugai not only thrives within the competitive pharmaceutical landscape but also contributes significantly to the global healthcare ecosystem.

Intrinsic Value
4 526.93 JPY
Overvaluation 35%
Intrinsic Value
Price

See Also

What is Chugai Pharmaceutical Co Ltd's Effect of Foreign Exchange Rates?
Effect of Foreign Exchange Rates
3.2B JPY

Based on the financial report for Sep 30, 2024, Chugai Pharmaceutical Co Ltd's Effect of Foreign Exchange Rates amounts to 3.2B JPY.

What is Chugai Pharmaceutical Co Ltd's Effect of Foreign Exchange Rates growth rate?
Effect of Foreign Exchange Rates CAGR 10Y
16%

Over the last year, the Effect of Foreign Exchange Rates growth was 10%. The average annual Effect of Foreign Exchange Rates growth rates for Chugai Pharmaceutical Co Ltd have been 6% over the past three years , and 16% over the past ten years .

Back to Top